

## PRESS RELEASE

**to-BBB receives Frost & Sullivan Technology Innovation Award**

Leiden, the Netherlands, 28 November 2012

**to-BBB, the Dutch brain drug delivery company, has been awarded the 2012 European CNS Targeted Drug Delivery Technology Innovation Award by Frost & Sullivan that is based on extensive research carried out by a team of renowned healthcare analysts.**

CNS disorders are a major cause of mortality and debilitation. With increasing prevalence of neurodegenerative diseases and incidence of acute conditions like stroke, there is a need to develop effective therapies to tackle diseases with a CNS component. Frost & Sullivan recognizes that despite the growing understanding of CNS related diseases and the extensive efforts gone into developing molecules that target disease pathways, pharmaceutical and biotech companies still face the fundamental challenge of achieving effective delivery to the brain because of the presence of the neuroprotective blood-brain barrier.

In order to address the challenges of CNS targeted delivery, to-BBB has developed an innovative technology platform (G-Technology®) that uniquely combines components that have already been extensively used in humans including a liposome-based drug delivery system and a targeting peptide ligand (glutathione).

The Frost & Sullivan Technology Innovation Award is a prestigious recognition of to-BBB's accomplishments in the CNS Targeted Drug Delivery field. As an independent, third-party, Frost & Sullivan recognizes to-BBB for delivering excellence and best practices in this challenging field.

“The technology platform has demonstrated success in clinical studies and the company is progressing rapidly with its in house drug pipeline,” says Ruplekha Pramodh Choudhurie, Senior Research Analyst Healthcare of Frost & Sullivan. “Taking into account the critical need for targeted delivery of drugs to the CNS and lack of effective and safe drug delivery modalities, to-BBB is well positioned to bring targeted CNS therapeutics to the clinic within a short time and with less regulatory hurdles due to the use of already FDA approved components in the delivery system.”

Pieter Gaillard, Chief Scientific Officer at to-BBB adds: “Based on the thorough research and benchmarking criteria used by Frost & Sullivan, to-BBB is honored to have received the CNS Targeted Drug Delivery award. It confirms the need for safe, non-invasive delivery techniques that can deliver drugs across the blood-brain barrier, and the suitability of the G-Technology platform to fulfill this need.”

The Frost & Sullivan Award Report is available on the website of to-BBB (<http://www.tobbb.com/company/Media>).



### **About Frost & Sullivan**

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit <http://www.frost.com>.

### **About to-BBB**

to-BBB is a clinical stage biotechnology company focusing on enhanced drug delivery across the blood-brain barrier. The Company is developing novel treatments for devastating brain disorders, such as brain cancer, neurodegenerative diseases and lysosomal storage diseases, by combining existing drugs with the G-Technology<sup>®</sup>, to-BBB's proprietary brain delivery platform. This technology combines the widely used drug delivery approach of pegylated liposomes with the endogenous tripeptide glutathione as targeting ligand in a novel and safe way. Together with several top tier pharma and biotech companies, to-BBB is investigating the versatility of the G-Technology for drugs that are unable to reach the brain at systemically tolerable therapeutic doses. to-BBB is applying the G-Technology for the delivery of doxorubicin for the treatment of brain cancer as its internal lead product 2B3-101 which is currently tested in a phase I/IIa trial.

to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).

### **Contact**

*Ajay Mistry, PhD*  
Head of Business Development

Phone: +44 7881 811 739  
E-mail: [AjayMistry@toBBB.com](mailto:AjayMistry@toBBB.com)

**to-BBB technologies BV**  
Niels Bohrweg 11  
2333 CA Leiden  
The Netherlands  
[www.toBBB.com](http://www.toBBB.com)

*Sijme Zeilemaker, MSc*  
Business Development Associate

Phone: +31 71 3322256  
E-mail: [SijmeZeilemaker@toBBB.com](mailto:SijmeZeilemaker@toBBB.com)

**to-BBB technologies BV**  
Niels Bohrweg 11  
2333 CA Leiden  
The Netherlands  
[www.toBBB.com](http://www.toBBB.com)

to-BBB will be moving to new premises as of 19 December 2012. The new address will be:

J.H. Oortweg 19  
2333 CH Leiden  
The Netherlands



**2012 European CNS Targeted Drug Delivery  
Technology Innovation Award**



FROST & SULLIVAN



50 Years of Growth, Innovation & Leadership